Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Lille, France Clinical Trials

A listing of Lille, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (18) clinical trials

Fluorouracil Cisplatin Cetuximab and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery

OBJECTIVES: Primary - To determine the maximum tolerated dose of fluorouracil and cisplatin when administered with cetuximab concurrently with esophageal radiotherapy. (Phase I) - To determine the complete histological response rate (after surgical resection). (Phase II) Secondary - To determine progression-free survival and overall survival. (Phase II) - To determine ...

Phase

0.0 miles

Learn More »

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.

Phase

0.0 miles

Learn More »

A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)

The study was redesigned to expand the number of patients analyzed during the Phase 1b stage of the study to determine a safe and effective dose of AG-120 administered with azacitidine for future studies. The Phase 1b (AG-120 expansion) stage will evaluate the safety, tolerability, and clinical activity of oral ...

Phase

0.0 miles

Learn More »

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

PHASE I: 3 cycles of Brentuximab Vedotin ICE every 3 weeks and one cycle of Brentuximab Vedotin alone at the doses described below. Cohorts of between three and six evaluable patients will be recruited at each dose level. Dose escalation rules: Treat 3 patients at level K If 0 patients ...

Phase

0.0 miles

Learn More »

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

The purpose of this study of INC280 and PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent or in combination with INC280 administered orally in adult patients with advanced hepatocellular carcinoma (HCC).

Phase

0.0 miles

Learn More »

PRTX-100-203 Open-Label Dose Escalation Study in Adult Patients With ITP

Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety profile. In vivo treatment with PRTX-100 has been shown to raise platelet counts in a mouse model ...

Phase

0.0 miles

Learn More »

Study to Assess the Safety Pharmacokinetics and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

This is a Phase 1b/2, double-blind (Principal Investigators and study subjects blinded, Sponsor unblinded), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in subjects with Acute Ischemic Stroke (AIS).

Phase

0.0 miles

Learn More »

Trial of Afatinib in Pediatric Tumours

Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort/Phase II part. The trial will consist of 2 parts: Dose finding part to determine the MTD Biomarker specific MTD expansion cohort/Phase II part to assess clinical anti-tumour activity in included tumour types

Phase

0.0 miles

Learn More »

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

The study consists of 5 cohorts: Cohort 1 (Single-Agent Dose-Finding) will use dose-escalation to find the recommended dose (RD) of lenvatinib using a time-to-event continual reassessment method (TiTE-CRM) design in children and adolescents with relapsed or refractory solid malignant tumors. When the RD is identified, Cohorts 2A, 2B, and 3A ...

Phase

0.0 miles

Learn More »

Open-Label Multicenter Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL

This is a multicenter, open-label, Phase 1/2 study that is being conducted in two parts. The Phase 1 part (closed to accrual as of January 25, 2016) is comprised of dose escalation and expansion parts to establish the MTD and/or the recommended Phase 2 dose (RP2D) when tazemetostat is given ...

Phase

0.0 miles

Learn More »